Monitoring outcomes of new disease modifying interventions and optimization of risk assessment in Alzheimer's disease

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Alzheimer's Disease
  • Age: Between 50 Year(s) - 122 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Female Participants not lactating or pregnant.
    2. Medication Requirements: Stable dose for at least 12 weeks prior to Baseline for those on acetylcholinesterase inhibitors or memantine for Alzheimer's Disease (AD).
    3. On treatment for Adulhem or Leqembi
    4. Other medications must have stable doses for at least 4 weeks prior to Baseline.
    5. Caregiver/Informant: Must have an identified caregiver or informant.
    6. Both participant and informant must provide written informed consent.

You may not be eligible for this study if the following are true:

    1. Other Neurological Conditions: Conditions contributing to cognitive impairment beyond AD.
    2. Recent Neurological Incidents: History of TIA, stroke, or seizures within 12 months of Screening.
    3. MRI Contraindications: Such as cardiac pacemakers/defibrillators, ferromagnetic metal implants, etc.
    4. Severe Sensory Impairments: Visual or hearing impairments affecting psychometric test performance.



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.